×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SLDB – solid biosciences inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SLDB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/7
08:00 am
sldb
Solid Biosciences to Participate at Upcoming Investor Conferences
Medium
Report
Solid Biosciences to Participate at Upcoming Investor Conferences
4/1
01:41 pm
sldb
Rett Syndrome Research Trust Appoints Genevieve Laforet, MD, PhD as Chief Medical Officer, Strengthening Leadership in Genetic Medicine Development
Low
Report
Rett Syndrome Research Trust Appoints Genevieve Laforet, MD, PhD as Chief Medical Officer, Strengthening Leadership in Genetic Medicine Development
3/26
05:49 am
sldb
Solid Biosciences (SLDB) was upgraded by Truist Financial Corporation to "strong-buy".
Medium
Report
Solid Biosciences (SLDB) was upgraded by Truist Financial Corporation to "strong-buy".
3/25
10:56 am
sldb
Solid Biosciences (SLDB) had its price target raised by JPMorgan Chase & Co. from $11.00 to $12.00. They now have an "overweight" rating on the stock.
Low
Report
Solid Biosciences (SLDB) had its price target raised by JPMorgan Chase & Co. from $11.00 to $12.00. They now have an "overweight" rating on the stock.
3/23
08:04 am
sldb
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
3/20
08:44 am
sldb
Solid Biosciences (SLDB) is now covered by Guggenheim. They set a "buy" rating and a $26.00 price target on the stock.
Medium
Report
Solid Biosciences (SLDB) is now covered by Guggenheim. They set a "buy" rating and a $26.00 price target on the stock.
3/20
08:26 am
sldb
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.
Medium
Report
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.
3/20
08:05 am
sldb
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $19.00 price target on the stock.
Medium
Report
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $19.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/10
04:11 pm
sldb
Form PRE 14A Solid Biosciences Inc. For: Jun 10
Medium
Report
Form PRE 14A Solid Biosciences Inc. For: Jun 10
4/10
04:09 pm
sldb
Form 8-K Solid Biosciences Inc. For: Apr 10
Medium
Report
Form 8-K Solid Biosciences Inc. For: Apr 10
4/2
04:05 pm
sldb
Form 4 Solid Biosciences Inc. For: Apr 02 Filed by: SMITH IAN F
Medium
Report
Form 4 Solid Biosciences Inc. For: Apr 02 Filed by: SMITH IAN F
4/1
06:07 am
sldb
Form EFFECT Solid Biosciences Inc.
Low
Report
Form EFFECT Solid Biosciences Inc.
4/1
06:07 am
sldb
Form EFFECT Solid Biosciences Inc.
Low
Report
Form EFFECT Solid Biosciences Inc.
3/19
05:05 pm
sldb
Form S-3 Solid Biosciences Inc.
Low
Report
Form S-3 Solid Biosciences Inc.
3/19
05:03 pm
sldb
Form S-3 Solid Biosciences Inc.
Low
Report
Form S-3 Solid Biosciences Inc.
3/19
04:11 pm
sldb
Form S-8 Solid Biosciences Inc.
Low
Report
Form S-8 Solid Biosciences Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/26
Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors
34.4%
8/16 Solid Biosciences Inc (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 33.5%
8/14 Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update 23.8%
5/14 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Chardan Capital from a "buy" rating to a "neutral" rating. They now have a $7.50 price target on the stock. 18.9%
10/11 Solid Biosciences Inc (NASDAQ: SLDB) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock. 11.2%
9/20 Solid Biosciences Inc (NASDAQ: SLDB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 11.2%
10/16 SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Solid Biosciences Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors 10.7%
7/29 Form 4 Solid Biosciences Inc. For: Jul 25 Filed by: Ganot Ilan 9.0%
8/27 Solid Biosciences Looks Like An Obvious Sell [Seeking Alpha] 8.7%
11/12 Solid Biosciences Inc (NASDAQ: SLDB) had its price target lowered by analysts at Credit Suisse Group AG from $6.00 to $2.00. They now have a "hold" rating on the stock. 7.4%
8/16 Solid Biosciences Inc (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 33.5%
8/14 Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update 23.8%
5/14 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Chardan Capital from a "buy" rating to a "neutral" rating. They now have a $7.50 price target on the stock. 18.9%
10/11 Solid Biosciences Inc (NASDAQ: SLDB) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock. 11.2%
9/20 Solid Biosciences Inc (NASDAQ: SLDB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 11.2%
10/16 SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Solid Biosciences Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors 10.7%
7/29 Form 4 Solid Biosciences Inc. For: Jul 25 Filed by: Ganot Ilan 9.0%
8/27 Solid Biosciences Looks Like An Obvious Sell [Seeking Alpha] 8.7%
11/12 Solid Biosciences Inc (NASDAQ: SLDB) had its price target lowered by analysts at Credit Suisse Group AG from $6.00 to $2.00. They now have a "hold" rating on the stock. 7.4%
TOP News Decliners
11/12
Solid Biosciences Provides SGT-001 Program Update
-74.4%
5/13 Q1/2019 3/31/2019 EPS -0.850 ZacksConsensus -0.610 ActVsEst (0.240) - Miss -28.6%
3/13 Form 4 Solid Biosciences Inc. For: Mar 11 Filed by: Ziolkowski Jennifer Lynn -21.1%
12/18 Solid Biosciences stock are up on DMD study news [MarketWatch] -20.1%
1/9 Form 8-K Solid Biosciences Inc. For: Jan 07 -14.6%
3/23 Solid Biosciences Inc (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock. -9.3%
7/26 Form 8-K Solid Biosciences Inc. For: Jul 25 -9.2%
3/20 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.9%
8/29 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Citigroup Inc from a "neutral" rating to a "sell" rating. They now have a $6.00 price target on the stock. -5.4%
7/31 Form D Solid Biosciences Inc. -5.3%
5/13 Q1/2019 3/31/2019 EPS -0.850 ZacksConsensus -0.610 ActVsEst (0.240) - Miss -28.6%
3/13 Form 4 Solid Biosciences Inc. For: Mar 11 Filed by: Ziolkowski Jennifer Lynn -21.1%
12/18 Solid Biosciences stock are up on DMD study news [MarketWatch] -20.1%
1/9 Form 8-K Solid Biosciences Inc. For: Jan 07 -14.6%
3/23 Solid Biosciences Inc (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock. -9.3%
7/26 Form 8-K Solid Biosciences Inc. For: Jul 25 -9.2%
3/20 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.9%
8/29 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Citigroup Inc from a "neutral" rating to a "sell" rating. They now have a $6.00 price target on the stock. -5.4%
7/31 Form D Solid Biosciences Inc. -5.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: